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osting by EAbstract Hereditary periodic fever syndromes, comprise a group of hereditary disorders with sim-
ilar clinical features of recurrent short episodes of fever associated with inﬂammatory manifestations.
These are usually self-limited in nature and occur in the absence of infection or autoimmune reaction.
Between attacks, patients feel well and regain their normal daily functions until the next episode
occurs. The episodes are usually associated with elevated serum levels of acute-phase reactants
(e.g., ﬁbrinogen, serum amyloid A [SAA]), an elevated erythrocyte sedimentation rate (ESR), and
leukocytosis. These illnesses represent inborn errors in the regulation of innate immunity thus sub-
stantiating the distinction from autoimmune disorders, which more directly affect the adaptive
immune system. Each of these disorders has a distinct genetic defect. Most of these proteins are mem-
bers of the Death Domain Superfamily and are involved in inﬂammation and apoptosis. These pro-
teins mediate the regulation of nuclear factor-kB (NF-kB), cell apoptosis, and interleukin 1b (IL-1b)
secretion through cross-regulated and common signaling pathways. Six periodic fever syndromes
have been characterized. Genetic defects, pathogenesis, epidemiology and management of these
fevers will be discussed.
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Hereditary periodic fever syndromes (HPFSs) are rare and dis-
tinct heritable disorders characterized by short and recurrent
attacks of fever and severe localized inﬂammation that occur
periodically or irregularly and that are not explained by usual
childhood infections. These attacks undergo spontaneous
remission without antibiotic, anti-inﬂammatory, or immuno-
suppressive treatment. Between attacks, patients feel well and
regain their normal daily functions until the next episode
occurs. The episodes are usually associated with elevated serumTable 1 Summarizes the gene symbols, chromosomal loci, protein
Syndrome Gene and Locus Pr
FMF MEFV, 16P13.3 Py
HIDS MVK, 12q24 M
TRAPS TNFRSF1, 12p13 TN
MWS NLRP3 (CIAS1), 1q44 Cr
FCAS NLRP3 (CIAS1), 1q44 Cr
CINCA NLRP3 (CIAS1), 1q44 Crlevels of acute-phase reactants (e.g., ﬁbrinogen, serum amyloid
A [SAA]), an elevated erythrocyte sedimentation rate (ESR),
and leukocytosis [1]. They were initially described as affecting
primarily the serosal and synovial surfaces and the skin, but
now recognized to include a somewhat broader distribution
of affected tissues [2]. They differ from autoimmune diseases
such as systemic lupus erythematosus and rheumatoid arthritis
in that they lack high-titer autoantibodies or antigen-speciﬁc T-
cells. They are termed autoinﬂammatory diseases [3]. Advances
in the genetics and molecular biology of the hereditary periodic
fever syndromes have deﬁned important new gene families andproducts, and modes of inheritance of these diseases [1].
otein Mode of Inheritance
rin, marenostrin Autosomal recessive
evalonate kinase (MK) Autosomal recessive
F-receptor type 1 Autosomal dominant
yopyrin (NALP3/ PYPAF1) Autosomal dominant
yopyrin (NALP3/ PYPAF1) Autosomal dominant
yopyrin (NALP3/ PYPAF1) Autosomal dominant
Nutritional genomics 119pathways in the regulation of innate immunity, thus substanti-
ating the distinction from autoimmune disorders, which more
directly affect the adaptive immune system [4].
2. Types
Six periodic fever diseases have been well characterized over
the last few years. They include familial mediterranean fever
(FMF), followed by tumor necrosis factor (TNF)–receptor-
associated periodic syndrome (TRAPS), and hyperimmuno-
globulinemia D syndrome (HIDS). Additional syndromes
include Muckle–Wells syndrome (MWS); familial cold
urticaria (FCU), known also as familial cold autoinﬂammato-
ry syndrome (FCAS); and chronic infantile neurological cuta-
neous and articular disease (CINCA), also known as neonatal
onset multisystemic inﬂammatory disease (NOMID) [5–8],
Table 1.
Another periodic fever syndrome is periodic fever, adenop-
athy, and pharyngitis with aphthous ulcerations (PFAPA), but
it is not classiﬁed as a human autoinﬂammatory syndrome [9].
The differential diagnosis for periodic fever spectrum of dis-
eases is wide and includes infectious, malignant, and autoim-
mune disorders, as well as factitious and iatrogenic fever. If
these attacks persist for longer than 1 year and, especially if
they are associated with a family history of periodic fever,
the possibility of HPFS should be raised [1].
3. Genetic defects and general pathogenesis
Each of these disorders has a distinct genetic defect which
leads to mutations in NAIP proteins. Most of these proteins
are members of the Death Domains Superfamily and are in-
volved in inﬂammation and apoptosis. These proteins mediate
the regulation of nuclear factor-kB (NF-kB), cell apoptosis,
and interleukin 1b (IL-1b) secretion through cross-regulated
and common signaling pathways [9].
HPFs are Mendelian disorders associated with sequence
variations in very few genes. These variations are mostly mis-
sense mutations with deleterious effects. The mutations involve
NALP proteins, also known as NLRPs, belong to the CAT-
ERPILLER protein family, like Toll-like receptors, involved
in the recognition of microbial molecules and the subsequent
activation of inﬂammatory and immune responses [10].
3.1. Familial mediterranean fever (FMF)
FMF, also known as recurrent hereditary polyserositis, [1], is
the most common entity among the group of periodic fever
syndromes[9].
3.1.1. Pathogenesis
The gene responsible for FMF is mapped to a small interval on
the short arm of chromosome 16p13.3. The FMF gene, desig-
nated MEFV (ME for Mediterranean and FV for fever). It is
approximately 10 KB with 10 exons that express a 3.7-kb tran-
script encoding a 781 amino acid protein known as pyrin, or
marenostrin, which is expressed in myeloid cells [9]; as MEFV
is expressed predominantly in granulocytes, monocytes,
dendritic cells, and in ﬁbroblasts derived from skin, perito-
neum, and synovium [11–13]. More than 50 mutations have
been discovered, mostly of missense type. The ﬁve most com-
mon mutations (M694V, V726A, M694I, M680I, andE148Q) are found in more than two thirds of Mediterranean
patients with FMF. The most common missense mutation is
M694V (substitution of methionine with valine at codon
694), which occurs in 20–67% of cases and is associated with
full penetrance. Homozygosity for M694V is associated with
a greater disease severity and a higher incidence of amyloido-
sis. The V726A mutation occurs in 7–35% of cases and is asso-
ciated with milder disease and a lower incidence of
amyloidosis. The E148Q mutation is associated with low pen-
etrance and very mild phenotype. These ﬁndings suggest that
phenotypic differences may reﬂect different mutations. As with
other recessive diseases, it is likely that some heterozygous pa-
tients may show attenuated clinical symptoms, with or without
increased levels of acute phase reactants [9].
3.1.2. Epidemiology
FMF predominantly affects populations living in the Mediter-
ranean region, especially North African Jews, Armenians,
Turks, and Arabs. Among Armenians with FMF, the spec-
trum of mutations is similar to that in the non-Ashkenazi
Jewish population [14]. The clinical picture of FMF in Arabs
appears to be distinct, and the range and distribution of
MEFV mutations are different from those noted in other eth-
nic groups [15].
Unlike the Jewish, Armenian, and Turkish populations,
Ozturk et al. [16] did not ﬁnd a single predominant mutation
in Egyptian patients with FMF. The diversity of mutations
among Egyptians was reported before [17] and could be related
to the heterogeneous origin of the Egyptian population and the
effect of different civilization marks (such as Romans,
Byzantines, and Ottomans beside the original inhabitants,
the Arabs) left on this country since ancient times because of
its unique location at the crossroads between Africa, Europe,
and Asia. In Egypt, there were ﬁve main founder mutations
accounting for the vast majority of cases of FMF which were
V726A, M694V, M680I, E148Q, and M694I [18]. Also R202Q
and P706 might be disease-causing mutations [16].
The male-to-female ratio of cases is about 1.5–2:1, raising
the possibility that the mutation has reduced penetrance in wo-
men. Many women report that attacks occur most commonly
with menses and disappears during pregnancy and return after
delivery. This pattern suggests that female sex hormones might
inﬂuence the disease [19]. Furthermore, the risk of renal amy-
loidosis is higher in men than in women [20,21].
Approximately 90% of patients are younger than 20 years,
and 60% of patients are younger than 10 years. Late-onset dis-
ease is usually more clinically benign than early-onset disease
[1].
3.1.3. Clinical picture
FMF is divided into two phenotypes, type 1 and 2:
 FMF type 1 is characterized by recurrent short episodes of
inﬂammation and serositis including fever, peritonitis, syno-
vitis, pleuritis, and, rarely, pericarditis and meningitis. The
symptoms vary among affected individuals, sometimes even
among members of the same family. Amyloidosis, which
can lead to renal failure, is the most severe complication
of FMF type 1.
 FMF type 2 is characterized by amyloidosis as the ﬁrst clin-
ical manifestation of disease in an otherwise asymptomatic
individual. [22–25].
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tacks that last 12 h to 4 days. The pain usually involves 1–2
of the following sites at a time: abdomen 90%, chest 40%,
joints 70%, muscles, scrotum 5%, and skin [1].
Abdominal attacks start with the sudden onset of fever and
pain affecting the entire abdomen [26]. The febrile joint
attacks, manifest as recurrent episodes of nondestructive acute
monoarthritis of short duration and most frequently involve
the large joints of lower extremities [27]. In about 1% of
patients, it is the sole disease manifestation. Myalgia is a fre-
quent ﬁnding in patients with familial Mediterranean fever
[1]. The febrile chest attacks manifest as pleuritis. Patients have
unilateral chest pain that increases on inspiration [28]. The
inﬂammation of the tunica vaginalis testis causes a picture of
acute scrotum. It usually results in self-limited, unilateral,
red painful swelling of the scrotum [1]. Erysipelas-like ery-
thema is characterized by fever and hot, tender, swollen, shar-
ply bordered red lesions that are typically 10–35 cm2 in area
and occur mainly on the legs, between the ankle and the knee,
or on the dorsum of the foot, that last 1–2 days. Isolated tem-
perature elevation lasting a few hours can occur without any
pain or inﬂammation [29].
3.1.4. Complications
Amyloidosis type AA amyloidosis is common in untreated
individuals. It presents with persistent, heavy proteinuria lead-
ing to nephrotic syndrome and progressive nephropathy lead-
ing to end-stage renal disease (ESRD). With increased
longevity of individuals with renal failure through dialysis
and/or renal transplantation, amyloid deposits are being found
in other organs as well [24,30]. Although this condition is
mainly related to the M694V homozygous genotype, it is also
reported in association with other genotypes that confer a rel-
atively mild form of the disease. Furthermore, renal amyloido-
sis can occur in asymptomatic individuals who do not have
attacks of serositis (phenotype II) [31].
The age of onset of FMF attacks appears to be lower in
persons with amyloidosis than in those without amyloidosis.
FMF-related manifestations of chest pain, arthritis, and
erysipelas-like erythema are more common in those with
amyloidosis. Long periods between disease onset and
diagnosis are associated with a high risk of developing
amyloidosis [32].
3.1.5. Diagnosis
The diagnostic criteria include [33]:
 Major criteria.
s Recurrent febrile episodes of peritonitis, synovitis, or
pleuritis.
s Amyloid-associated protein (AA)–type amyloidosis with
no predisposing disease.
s Favorable response to continuous colchicine treatment.
 Minor criteria.
s Recurrent febrile episodes.
s Erysipelaslike erythema.
s FMF in a ﬁrst-degree relatives.
A deﬁnitive diagnosis is based on two major or one major
and two minor criteria. A probable diagnosis is based on
one major and one minor criteria. Most cases are currently
conﬁrmed with molecular testing [33].3.1.5.1. Laboratory studies. Targeted mutation analysis and
sequence analysis of selected exons [29].
During attacks, there is increased levels of acute-phase reac-
tants (C-reactive protein, serumamyloidA, ﬁbrinogen, haptoglo-
bin, C3, and C4). Urinalysis demonstrates transient albuminuria
and microscopic hematuria. The synovial ﬂuid is cloudy, ﬁlled
with polymorphonuclear (PMN) cells, and sterile [1].
3.1.6. Management
3.1.6.1. Treatment of manifestations. Febrile and inﬂammatory
episodes are usually treated with nonsteroidal anti-inﬂamma-
tory drugs (NSAIDs). ESRD should be treated as for other
causes of renal failure. The long-term outcome of live related-
donor renal transplantation in individualswith FMF-amyloido-
sis is similar to that in the general transplant population [34].
3.1.6.2. Prevention of primary manifestations.
 Colchicine therapy
Homozygous or compound heterozygous for the mutation
Met694Val should be treated with colchicine. Colchicine is
given orally for life, 1–2 mg/day in adults. Children may need
0.5–1 mg/day according to age and weight [29]. Individuals
who do not have the mutation and who are only mildly
affected should either be treated with colchicine or monitored
every 6 months for the presence of proteinuria. Continuous
treatment with colchicine appears to be less indicated for indi-
viduals who are homozygous or compound heterozygous for
the mutation Glu148Gln [29].
Complications of colchicine occasionally include myopa-
thy, toxic epidermal necrolysis-like reaction and oligospermia.
Colchicine should be continued in pregnancy. Treatment with
colchicine 1 mg/day prevents renal amyloidosis even if the
FMF attacks do not respond to the drug.
 Anakinra therapy
It is an IL-1-receptor inhibitor which offers a recently safe
and effective treatment (100 mg daily or every other day) for
persons who do not respond to colchicine [35–41]. This drug
is expensive and has mild side effects, such as painful local
reactions at the site of injections and possibly bronchopulmo-
nary infection complications. Also further studies are needed if
it is to be taken continuously as required in severely affected
individuals with FMF.
3.2. Hyperimmunoglobulinemia D with periodic fever syndrome
(HIDS)
The disorder has also been described as a variant of Still’s dis-
ease [42,43] or as etiocholanolone fever [44].
3.2.1. Pathogenesis
It is caused by mutations in the mevalonate kinase (MVK)
gene found on chromosome 12 at 12q24. Mevalonate kinase
is an enzyme that enhances the metabolism of mevalonic acid,
an intermediary product of cholesterol and isoprenoid synthe-
sis pathways. It is speculated that shortage of isoprenoid end
products contributes to increased secretion of IL-1b, which
subsequently leads to overt inﬂammation and fever. More than
40 different mutations of the MVK gene have been reported.
Nutritional genomics 121The most common mutation is V377I, likely of Dutch origin.
Mutations are associated with decreased activity of mevalo-
nate kinase in lymphocytes, leading to increased plasma levels
of mevalonic acid, which is excreted in large amounts in the ur-
ine [9].3.2.2. Epidemiology
This condition is reported primarily among families of Euro-
pean descent, especially Dutch and French [9]. The male-to-fe-
male ratio was equal in one study [45] but about 3:2 in another
large series [46], which raises the possibility of reduced pene-
trance in women. Most patients have attacks before the end
of their ﬁrst year of life (median, 0.5 years). The attacks persist
throughout life, although patients have a reduction in intensity
and frequency of attacks after adolescence [1].
3.2.3. Clinical picture
Episodic attacks of fever occur every 4–8 weeks [1], last 3–7
days and are sometimes triggered by childhood immunizations.
Minor trauma, surgery, and stress are known aggravating con-
ditions [47]. Attacks manifest as high, spiking fever and is pre-
ceded by chills in 76% of patients [46]. Abdominal pain was
reported in 72%, vomiting in 56%, diarrhea in 82%, and head-
ache in 52%, polyarthralgia in 80% and a nondestructive
arthritis in 68% of patients, skin lesions in 82%, and serositis
in a minority of patients. Surprisingly, amyloidosis has not
been recorded in any of the patients with this syndrome [1].
3.2.3.1. Diagnosis. Diagnostic criteria [46,47]:
 Constant: High IgD level (>100 U/mL) measured on two
occasions at least 1 month apart.
 During attacks:
s Elevated erythrocyte sedimentation rate (ESR) and
leukocytosis.
s Abrupt onset of fever (temperature at least 38.5 C).
s Recurrent attacks.
s Elevated immunoglobulin A (IgA) level.
s Cervical lymphadenopathy.
s Abdominal distress (vomiting, diarrhea, pain) ([67]).
s Skin manifestations (erythematous macules and
papules).
s Arthralgias and/or arthritis.
s Splenomegaly.
s Measure urinary mevalonic acid (slight elevation).
s Genetic testing to screen for the most common V377I
mutation.
s In rare cases, measure MK activity.3.2.4. Differential diagnosis
Mevalonic aciduria (MVA) is typically a disease of infantile
onset. It is characterized by psychomotor retardation, ataxia,
failure to thrive, cataracts, and dysmorphic features [48–50].
Patients also have severe periodic fever attacks.
3.2.5. Treatment
Treatment is largely supportive because various standard anti-
inﬂammatory drugs (including colchicine and steroids) fail to
suppress the attacks [1]. Thalidomide resulted in a nonsigniﬁ-
cant decrease of acute phase protein synthesis but without an
effect on the attack rate [47]. A trial of simvastatin showed abeneﬁcial clinical effect in ﬁve of six patients [9] and a decrease
in the urinary mevalonic acid concentration in all patients. No
adverse effects were observed [1]
3.3. Tumor necrosis factor receptor-associated periodic
syndrome (TRAPs)
This syndrome was previously known by other names, includ-
ing (Familial Hibernian fever, Familial periodic fever, and
Autosomal dominant recurrent fever [9].
3.3.1. Pathogenesis
TRAPs is an autosomal dominant periodic fever It is caused
by mutation in the soluble TNF receptor superfamily 1A gene,
TNFRSF1A. It is on chromosome 12 at 12p13 and encodes for
type 1A TNF receptor protein. More than 40 different muta-
tions of the gene have been reported [9]. Most mutations in
TNFRSF1A mediate their effect via decreased shedding of
TNFRSF1A, thereby decreasing the amount of soluble recep-
tor available to bind soluble TNF and subsequently initiate
and maintain the inﬂammatory response. Defective shedding
only partially explains the pathophysiologic mechanism of
TRAPs because some mutations have normal shedding [51].
The dramatic response for etanercept, an anti-TNF agent, sug-
gests that TNF plays a critical role in the inﬂammatory process
of this disease [1].3.3.2. Epidemiology
Most patients are of northern European descent. However
mutations have been reported among patients from different
ethnicities, including African American, French, Belgian,
Dutch, Arab, Jewish, Irish, Scottish, and many other ethnici-
ties [52].
A male-to-female ratio of 3:2 is reported [52]. The reason
that women are more protected than men is still unknown [1].
Age ranges from 2 weeks to 53 years (median 3 years). The
age of onset varies within and among families.
3.3.3. Clinical picture
On average, the attacks occur once every 6 weeks and last
longer than 1 week. Few patients have daily pain without a
clear resolution of symptoms. Abdominal and chest pain occur
in 90% and 60% of patients, respectively. Arthralgia of the
large joints is common, but arthritis is rare. Painful unilateral
or bilateral conjunctivitis and periorbital edema are also com-
mon. In men, scrotal pain during attacks is reported, and the
incidence of inguinal hernia is increased for unknown reasons.
The myalgias are severely disabling and are a constant feature.
Myalgias usually start the attacks and migrate centrifugally.
About 84% of patients have tender, migratory erythematous
patches, which typically overlie areas of myalgia and lasting
for 4–21 days [53]. The prolonged attacks, conjunctivitis, and
localized myalgias differentiate the TRAPS from the other syn-
dromes of periodic fever [54,55]. Amyloidosis develops in up to
25% of the patients, depending on the speciﬁc gene mutation
and duration of attacks [9].3.3.4. Diagnostic criteria [52]
 Recurrent episodes of inﬂammatory symptoms spanning a
period longer than 6 months.
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s Abdominal pains.
s Migratory myalgia.
s Migratory erythematous patches.
s Conjunctivitis, periorbital edema.
s Chest pain.
s Arthralgia or arthritis.
 Episodes last longer than 5 days on a average.
 Responsive to glucocorticoids but not colchicines.
 Affected family members.
 Any ethnicity.
Patients usually report an increased severity with physical
or emotional stress or after physical trauma.
3.3.5. Laboratory studies
Increased levels of acute-phase reactants. The immunoglobulin
D (IgD) level may be elevated (<100 IU/mL), and levels of
soluble TNFRSF1A in the serum may be reduced during
and between attacks. Polyclonal gammopathy may also be
present [1].
3.3.6. Medications
 Etanercept (Enbrel) binds to TNF and blocks its interaction
with cell-surface TNF receptors, rendering TNF biologi-
cally inactive. It modulates biologic responses that TNF
induces or regulates.
 Prednisone.
3.4. The Cryopyrinopathies
The cryopryinopathies are a spectrum of clinical disorders
caused by mutations in CIAS1 [56–59] a nine-exon gene on
chromosome 1q. Although a number of overlapping syn-
dromes have been described, three relatively distinct clinical
disorders are recognized: familial cold autoinﬂammatory syn-
drome (FCAS), Muckle–Wells syndrome (MWS), and neona-
tal-onset multisystem inﬂammatory disease (NOMID, also
known as chronic infantile neurologic cutaneous and arthrop-
athy [CINCA] syndrome). An urticaria-like rash is common to
all of the cryopyrinopathies and is characterized histologically
by inﬁltrates of lymphocytes and neutrophils rather than mast
cells, indicating that it is not true urticaria [4,60]. The onset of
these syndromes occurs neonatally or during early childhood,
usually as a generalized urticaria-like skin rash associated with
an intense acute-phase reaction, and different inﬂammatory
manifestations can be observed for each clinical entity [61].
The common genetic basis for these syndromes that has
been observed by means of the identiﬁcation of dominantly
inherited mutations in the NLRP3 gene (formerly known as
CIAS1, PYPAF1, or NALP3), which encodes for the cryopy-
rin protein, a key component of the inﬂammasome [57–59]
support the hypothesis that the 3 CAPS diseases actually rep-
resent different points along a disease severity spectrum, where
FCAS represents the mildest phenotype, MWS the intermedi-
ate one, and CINCA/NOMID the severest [60]. Supporting
this hypothesis, some clinical cases of overlapping FCAS-
MWS and MWS-CINCA/NOMID syndromes have been
reported [62,63].3.4.1. Muckle–Wells Syndrome
It characterized by periodic episodes of non itchy skin rash, fe-
ver, joint pain, conjunctivitis, progressive hearing loss, and
kidney damage [64]. Patients have recurrent ‘‘ﬂare-ups’’ that
arise spontaneously or be triggered by cold, heat, fatigue, or
other stresses.
Hearing loss is caused by progressive nerve damage (sensori-
neural deafness) typically becomes apparent during the teenage
years. Amyloidosis cause progressive kidney damage in about
one-third of people and these deposits may also damage other
organs. In addition, pigmented skin lesions may occur [65].
3.4.1.1. Diagnosis. History of acute febrile inﬂammatory at-
tacks that last 24–72 h that result in abdominal pain, polyarth-
ralgias, or arthritis (of large joints), myalgia, urticaria (mostly
on the trunk and extremities), and conjunctivitis. Late in the
course of the disease, sensorineural deafness occurs. This fea-
ture distinguishes Muckle–Wells syndrome from other inﬂam-
matory disorders. After several years, amyloidosis of the AA
type develops.
3.4.1.2. Differential Diagnosis. It includes other HPFSs, Alport
syndrome (which has the common features of renal, ear, and
ocular involvement), amyloidosis, conjunctivitis, and arthritis
[1].
Laboratory tasting: mutation detection. To date, more than
90% of mutations in CAPS have been identiﬁed in exon 3 of
the NLRP3 (CIAS1) gene [1].
3.4.1.3. Medication.
 The drug of choice for is a selective recombinant IL-1
receptor antagonist, Rilonacept. Common adverse effects
include injection site reaction and upper respiratory tract
infections. It may interfere with immune response to
infections, and serious, life-threatening infections have
been reported [1].
 Anakinra, an interleukin 1 receptor antagonist, can lead
to an improvement in hearing loss [1,66].
Live vaccines should not be given concurrently [1].
3.4.2. Familial Cold Autoinﬂammatory Syndrome (FCAS)
(familial cold urticaria)
3.4.2.1. Diagnosis. Recurrent urticarial rash is the most consis-
tent trait occurring in all affected subjects. Additional recur-
rent fever and chills (93%), polyarthralgia (96%), and
conjunctivitis (84%). Other commonly reported symptoms
after exposure to cold include profuse sweating (78%), drows-
iness (67%), headache (58%), extreme thirst (53%), nausea
(51%), and myalgia [57]. Arthritis was not reported as a fea-
ture of this disease.3.4.2.2. Differential Diagnosis.
 Acquired cold urticaria (ACU) is one of the most common
forms of physical urticaria. The pathophysiology of ACU
involves mast-cell degranulation and histamine effects.
ACU typically occurs in adulthood and spontaneously
resolves. It develops within minutes of direct contact with
cold, resolves within hours, and can be accompanied by
angioedema, wheezing, and hypotension [1].
 Other HPFS, especially MWS should be considered.
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 Serum IL-6 concentrations may be high.
 Numbers of mast cells and tissue histamine levels are nor-
mal [1].3.4.2.4. Other tests.
 The ice cube test is performed by placing an ice cube
directly on the skin for 5 min. Patients with the disease have
no urticaria in response.
 Mutations detection in exon 3 of the NLRP3 (CIAS1) gene.
 Treatment
Recombinant IL-1 receptor antagonists (e.g., rilonacept,
anakinra, and canakinumab).
3.4.3. Chronic infantile neurologic, cutaneous, articular
syndrome (CINCA)
It is also known as neonatal-onset multisystem inﬂammatory
disease (NOMID) [68].
3.4.3.1. History. It is characterized by the triad of skin rash,
chronic aseptic meningitis, and arthropathy [69,70]. The typi-
cal features include a persistent and migratory urticarial rash
(which is often present from birth), fever, adenopathy, hepato-
splenomegaly, and a severe and deforming arthropathy (which
predominantly affects the large joints). Short episodes of recur-
rent fevers frequently occur. The arthropathy starts early in life
and has distinctive radiographic ﬁndings of premature patellar
and epiphyseal long-bone ossiﬁcation and resultant osseous
overgrowth that leads to severe joint contractures and disabil-
ity [71,72].
Progressive neurologic impairment results from chronic
aseptic meningitis caused by polymorphonuclear neutrophil
(PMN) inﬁltration. Neurologic manifestations include pro-
gressive visual defect and high-frequency hearing loss (which
frequently occurs with age), cerebral ventricular dilatation,
cerebral atrophy, and mental retardation.
3.4.3.2. Physical examination. Include fever, urticaria like skin
rash, splenomegaly and lymphadenopathy, dysmorphic fea-
tures (saddle-back nose, frontal bossing, and protruding eyes),
short stature with short and thick extremities, macrocephaly,
ﬁnger clubbing, and joint contractures (especially in the knees)
without evidence of synovial thickening on palpation.
Funduscopic examination may reveal papilledema and uveitis.
3.4.3.3. Laboratory studies.
 Serum IL-6 concentrations may be high.
 Numbers of mast cells and tissue histamine levels are nor-
mal [1]
 The ice cube test: no urticaria in response.
3.4.3.4. Medication.
 Treatment with colchicine, NSAIDs, and glucocorticoids
may provide some relief.
 Remarkable responses to anakinra in 3 family members with
MWS and 18 patients with CINCA have been reported [9].3.5. Pyogenic arthritis, Pyoderma gangrenosum, and Acne
(PAPA) and Blau syndromes
PAPA is an autosomal dominant disorder with mutations in
the gene encoding the adaptor protein proline serine threoninephosphatase-interacting protein (PSTPIP1) located on chro-
mosome 15 at 15q24.
Blau syndrome autosomal dominant disorder that manifests
with early-onset granulomatous arthritis, uveitis, rash, and
ﬂexion contractures at the ﬁngers associated with mutations
in the gene encoding CARD15 (caspase recruitment domain
15 protein), known also as NOD2 (nucleotide-binding oligo-
merization domain 2 protein) located on chromosome 16 at
16q12. These two syndromes are additional rare members of
the hereditary periodic fever syndromes family [9].
3.6. Marshall’s syndrome or PFAPA (periodic fever, aphthous
stomatitis, pharyngitis, cervical adenitis) syndrome
It is a pediatric periodic disease characterized by recurrent feb-
rile episodes associated with head and neck symptoms. The
origin of this syndrome, which can last for several years, is un-
known. During healthy periods, patients grow normally [9].
3.6.1. Clinical picture
PFAPA occurs sporadically with no ethnic predilection. Symp-
toms begin around 2–6 years of age and include fever, malaise,
exudative appearing tonsillitis with negative throat cultures,
cervical lymphadenopathy, and aphthae, and, less commonly,
headache, abdominal pain, and arthralgia. The episodes last 4–
6 days, regardless of antipyretic or antibiotic treatment, and
occur at a frequency of 8–12 episodes/year. Findings during
the episodes may include mild hepatosplenomegaly, mild leu-
kocytosis, and elevated acute phase reactants. Both the fre-
quency and intensity of the episodes diminish over time [9,73].
3.6.2. Diagnostic criteria [74]
Regularly recurring fevers with an early age of onset (<5 years
of age).
Symptoms in the absence of upper respiratory tract infec-
tion with at least one of the following clinical signs:
(a) aphthous stomatitis;
(b) cervical lymphadenitis and
(c) pharyngitis.Exclusion of cyclic neutropenia.
Completely asymptomatic interval between episodes.
Normal growth and development.3.6.3. Diagnosis
 Cultures from the oropharynx for bacterial, fungal, and
viral pathogens;
 Chest radiography and
 Laboratory studies: leukocytosis and an elevated erythro-
cyte sedimentation rate during febrile attacks [73].3.6.4. Treatment
Resolution of symptoms within 24 h after a single dose of
prednisone (1–2 mg/kg) or bethamethasone (0.3 mg/kg). Com-
plete resolution has also been reported after tonsillectomy.
Affected children grow normally and have spontaneous resolu-
tion within 4–8 years with no long-term sequelae [9].
4. Conclusion
Some of these fevers are not rare and should be put in mind in
deferential diagnosis of recurrent fever.
124 R.M. Shawky, N.E.A. GaboonThey should be differentiated from other causes of acute
abdomen, arthralgia, pleuritic pain, other autoimmune dis-
eases such as systemic lupus erythematosus and rheumatoid
arthritis in that they lack high-titer autoantibodies or anti-
gen-speciﬁc T-cells.
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